Intranasal Drug Delivery Devices Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The intranasal drug delivery devices market size has grown strongly in recent years. It will grow from $60.27 billion in 2024 to $65.59 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to rise in chronic respiratory diseases, patient preference and compliance, convenience in self-administration, pediatric applications, market expansion in allergic rhinitis treatment, wider range of indications.

The intranasal drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $92.05 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to increasing geriatric population, rising global respiratory issues, expanding applications in neurological disorders, personalized medicine trends, preventive healthcare initiatives, market penetration in emerging economies. Major trends in the forecast period include advances in formulation technologies, focus on pediatric and geriatric applications, rise in self-administration devices, nasal powder inhalers, incorporation of biologics and peptides.

The rising incidence of chronic diseases is anticipated to drive the growth of the intranasal drug delivery devices market in the coming years. Chronic diseases are defined as conditions lasting one year or more that require ongoing medical care, restrict daily activities, or both. Intranasal drug delivery devices are employed to manage chronic diseases by providing a non-invasive and effective means of administering medications. These devices enable medications to be delivered directly to the targeted area, offering convenience, ease of use, and promoting rapid absorption. For example, in June 2024, the National Health Service (NHS), a UK-based government agency, reported that in 2023, over half a million (549,000) additional individuals in England were identified as being at risk of developing type 2 diabetes. This brought the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a general practitioner to 3,615,330, marking a significant increase from 3,065,825 in 2022 and representing nearly a 20% rise. Therefore, the growing prevalence of chronic diseases is fueling the expansion of the intranasal drug delivery devices market.

The growing demand for non-invasive drug delivery methods is also expected to contribute to the expansion of the intranasal drug delivery device market. Non-invasive drug delivery involves administering pharmaceutical substances into the body without the need for skin or mucous membrane penetration or incision. Intranasal drug delivery devices play a crucial role in facilitating this approach, making it easy and effective to administer drugs through the nose. Leveraging the nose's extensive blood vessel network and ensuring fast absorption, these devices enhance drug bioavailability, improve patient adherence, and eliminate the need for invasive procedures. For example, data from The Aesthetic Society in August 2023 highlighted a significant increase in nonsurgical procedures in the U.S., with body contouring, skin treatment, toxins, and micro-needling showing growth rates of 31%, 26%, 24%, and 23%, respectively, in 2022. As a result, the growing demand for non-invasive drug delivery methods is a key driver for the expansion of the intranasal drug delivery device market.

Major pharmaceutical companies in the nasal drug delivery technology market are actively engaged in developing new and improved products to offer innovative drug administration methods and maintain their market position. For instance, in January 2023, AptarGroup, Inc., a US-based drug delivery and pharmaceutical company, introduced APF Futurity, the first recyclable, metal-free, multidose nasal spray for delivering nasal saline and similar over-the-counter (OTC) formulations. This product, made from polyolefin materials and devoid of metal components or recycling disruptors, reduces the need for separation in recycling streams and supports a higher grade of recycled materials. Notably, APF Futurity is a highly recyclable nasal spray pump that has obtained Class AA certification from cyclos-HTP for recycling streams in Europe.

In March 2022, Sandoz AG, a Switzerland-based biopharmaceutical company under the Novartis Group, acquired Coalesce Product Development Limited for an undisclosed amount. This strategic move aims to enhance Sandoz's capabilities in inhalation drug delivery, add a commercial-stage product to its portfolio, and expedite the development and commercialization of intranasal drug delivery devices. Coalesce Product Development Limited, based in the UK, specializes in drug delivery device development, including nasal drug delivery.

Major companies operating in the intranasal drug delivery devices market report are Johnson and Johnson Inc., Merck and Co.Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline PLC, 3M Company, Becton, Dickinson and Company, Teva Pharmaceutical Industries Ltd., AptarGroup Inc., West Pharmaceutical Services Inc., Teleflex Incorporated, Recipharm AB, Nemera Development S.A., Consort Medical plc., Vectura Group PLC, Douglas Pharmaceuticals Ltd., Avanir Pharmaceuticals, OptiNoset Inc., Flamel Technologies, Aegis Therapeutics LLC, Sonoma Pharmaceuticals, PendoPharm Inc., Kurve Technology Inc., Impel NeuroPharma, Impexium Medical Products, B.F. Ascher and Company Inc., ENT Technologies Pty. Ltd., Neurelis Inc., Generex Biotechnology Corporation.

North America was the largest region in the intranasal drug delivery devices market in 2024. The regions covered in the intranasal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intranasal drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intranasal drug delivery devices market consists of sales of nasal sprays, nasal powder devices, nasal antipsychotic medications, nasal epinephrine devices, nasal drops, and nasal inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Intranasal drug delivery devices are medical instruments designed to administer medications into the nasal cavity. These devices are specifically created to deliver medications directly to the highly vascularized nasal mucosa, which boasts a substantial surface area, facilitating rapid absorption of the drug into the bloodstream. Intranasal drug delivery devices are capable of delivering drugs or therapeutic substances in various forms, including sprays, powders, or liquid solutions, directly into the nasal cavity.

The primary products within the realm of intranasal drug delivery devices include powder delivery devices, liquid delivery devices, pressurized metered-dose inhalers, and other related devices. Powder delivery devices, a subtype of medical or pharmaceutical devices, are designed for administering medications in unit-dose or multi-dose forms and find applications in various medical conditions such as chronic obstructive pulmonary disease (COPD), rhinitis, cystic fibrosis, nasal congestion, asthma, among others. The end users of these devices include hospitals, clinics, homecare, and other healthcare settings.

The intranasal drug delivery devices market research report is one of a series of new reports that provides intranasal drug delivery devices market statistics, including intranasal drug delivery devices industry global market size, regional shares, competitors with a intranasal drug delivery devices market share, detailed intranasal drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the intranasal drug delivery devices industry. This intranasal drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.